These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 32404559)
1. Secretogranin III upregulation is involved in parkinsonian toxin-mediated astroglia activation. Zhan X; Wen G; Jiang E; Li F; Wu X; Pang H J Toxicol Sci; 2020; 45(5):271-280. PubMed ID: 32404559 [TBL] [Abstract][Full Text] [Related]
2. Effects of PQ's cytotoxicity on secretory vesicles in astroglia: Expression alternation of secretogranin II and its potential interaction with intracellular factors. Zhan X; Li F; Chu Q; Pang H Biochem Biophys Res Commun; 2018 Mar; 497(2):675-682. PubMed ID: 29454966 [TBL] [Abstract][Full Text] [Related]
3. Secretogranin III may be an indicator of paraquat-induced astrocyte activation and affects the recruitment of BDNF during this process. Zhan X; Li F; Chu Q; Pang H Int J Mol Med; 2018 Dec; 42(6):3622-3630. PubMed ID: 30280190 [TBL] [Abstract][Full Text] [Related]
4. Dysregulated expression of secretogranin III is involved in neurotoxin-induced dopaminergic neuron apoptosis. Li F; Tian X; Zhou Y; Zhu L; Wang B; Ding M; Pang H J Neurosci Res; 2012 Dec; 90(12):2237-46. PubMed ID: 22987761 [TBL] [Abstract][Full Text] [Related]
5. Secretogranin II binds to secretogranin III and forms secretory granules with orexin, neuropeptide Y, and POMC. Hotta K; Hosaka M; Tanabe A; Takeuchi T J Endocrinol; 2009 Jul; 202(1):111-21. PubMed ID: 19357184 [TBL] [Abstract][Full Text] [Related]
6. Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model. Fujita A; Yamaguchi H; Yamasaki R; Cui Y; Matsuoka Y; Yamada KI; Kira JI J Neuroinflammation; 2018 Aug; 15(1):227. PubMed ID: 30103794 [TBL] [Abstract][Full Text] [Related]
8. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells. Otto D; Unsicker K Glia; 1994 May; 11(1):47-56. PubMed ID: 8070894 [TBL] [Abstract][Full Text] [Related]
9. Regulation of connexin-43, GFAP, and FGF-2 is not accompanied by changes in astroglial coupling in MPTP-lesioned, FGF-2-treated parkinsonian mice. Rufer M; Wirth SB; Hofer A; Dermietzel R; Pastor A; Kettenmann H; Unsicker K J Neurosci Res; 1996 Dec; 46(5):606-17. PubMed ID: 8951672 [TBL] [Abstract][Full Text] [Related]
10. Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia. Zhang P; Lokuta KM; Turner DE; Liu B J Neurochem; 2010 Jan; 112(2):434-43. PubMed ID: 19895668 [TBL] [Abstract][Full Text] [Related]
11. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056 [TBL] [Abstract][Full Text] [Related]
12. Astrocytic JWA deletion exacerbates dopaminergic neurodegeneration by decreasing glutamate transporters in mice. Wang R; Zhao X; Xu J; Wen Y; Li A; Lu M; Zhou J Cell Death Dis; 2018 Mar; 9(3):352. PubMed ID: 29500411 [TBL] [Abstract][Full Text] [Related]
13. FGF-2-mediated protection of cultured mesencephalic dopaminergic neurons against MPTP and MPP+: specificity and impact of culture conditions, non-dopaminergic neurons, and astroglial cells. Otto D; Unsicker K J Neurosci Res; 1993 Mar; 34(4):382-93. PubMed ID: 8097265 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. O'Callaghan JP; Miller DB; Reinhard JF Brain Res; 1990 Jun; 521(1-2):73-80. PubMed ID: 1976416 [TBL] [Abstract][Full Text] [Related]
15. Silibinin suppresses astroglial activation in a mouse model of acute Parkinson's disease by modulating the ERK and JNK signaling pathways. Lee Y; Chun HJ; Lee KM; Jung YS; Lee J Brain Res; 2015 Nov; 1627():233-42. PubMed ID: 26434409 [TBL] [Abstract][Full Text] [Related]
16. Proteomic characterization of secretory granules in dopaminergic neurons indicates chromogranin/secretogranin-mediated protein processing impairment in Parkinson's disease. Wen G; Pang H; Wu X; Jiang E; Zhang X; Zhan X Aging (Albany NY); 2021 Aug; 13(16):20335-20358. PubMed ID: 34420933 [TBL] [Abstract][Full Text] [Related]
17. Clathrin-Dependent Uptake of Paraquat into SH-SY5Y Cells and Its Internalization into Different Subcellular Compartments. Li F; Tian X; Zhan X; Wang B; Ding M; Pang H Neurotox Res; 2017 Aug; 32(2):204-217. PubMed ID: 28303546 [TBL] [Abstract][Full Text] [Related]
18. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease]. Matsubara K Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975 [TBL] [Abstract][Full Text] [Related]
19. Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. Litim N; Morissette M; Caruso D; Melcangi RC; Di Paolo T J Steroid Biochem Mol Biol; 2017 Nov; 174():242-256. PubMed ID: 28982631 [TBL] [Abstract][Full Text] [Related]
20. Identification of brain-derived neurotrophic factor in nestin-expressing astroglial cells in the neostriatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Chen LW; Hu HJ; Liu HL; Yung KK; Chan YS Neuroscience; 2004; 126(4):941-53. PubMed ID: 15207328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]